Kashyap, S.R., Bhatt, D.L., Wolski, K., Watanabe, R.M., Abdul-Ghani, M., Abood, B., Pothier, C.E., Brethauer, S., Nissen, S., Gupta, M., Kirwan, J.P. and Schauer, P.R. (2013) Metabolic Effects of Bariatric Surgery in Patients with Moderate Obesity and Type 2 Diabetes: Analysis of a Randomized Control Trial Comparing Surgery with Intensive Medical Treatment. Diabetes Care, 36, 2175-2182.
http://dx.doi.org/10.2337/dc12-1596

has been cited by the following article:

• TITLE: Progressive β Cell Failure in Type 2 Diabetes Mellitus: Microvascular Pancreatic Isletopathy?

  AUTHORS: Udaya M. Kabadi, Mary U. Kabadi, Sommany Weber, Aaron Bubolz, Edward Finnerty

  KEYWORDS: Type 2 Diabetes, Beta Cell Failure, Pancreatic Isletopathy

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.5 No.1, January 13, 2015

  ABSTRACT: Background: UKPDS suggested relentless deterioration of β cell function as a part of natural course of type 2 diabetes mellitus. However, the course was apparently not universal since many patients maintained glycemic goal (HbA1c β cell failure occurred around the same time as the time of onset of microvascular complications. Finally, the exact mechanism of progressive β cell failure remains to be defined. It is plausible that β cell failure may be due to fibrosis of pancreatic islets secondary to microangiopathy since no organ or tissue is exempt from this complication. Objective: To assess epidemiologic correlation between presence of b cell failure and microvascular complications by determining the prevalence of β cell failure in subjects with type 2 diabetes with increasing number of known microvascular complications. Methods: 650 Subjects with ages 40-75 years and duration of DM 4-23 years were divided into 4 groups according to number of microvascular complications, e.g. retinopathy, nephropathy, and neuropathy. β cell failure (β -ve ) is defined as HbA1c > 7.0% with any therapy or HbA1c β cell function is deemed “preserved” (β + ve) with HbA1c b cell failure progressively rose with increasing number of microvascular complications from 0 to 2 with no further significant rise with 3 complications whereas subjects with preserved β cell function declined with increasing number of microvascular complications (p β cell failure (p β cell failure/β cell preserved with increasing number of microvascular complications as well as the greater duration of Diabetes. However, a significantly (p β cell failure persisted for rising number of microvascular complications even after eliminating the influence of age and duration of diabetes. Conclusion: β cell failure may be a manifestation of microvascular pancreatic isletopathy similar to other microvascular complications.